A drug best known for preventing organ transplant rejection just produced an unexpected result in Alzheimer’s research. Scientists at the University of Missouri found that four weeks of low-dose rapamycin improved brain blood flow in middle-aged adults carrying a genetic risk factor for the disease.
The surprising part? The benefit appeared in people carrying the APOE4 variant, particularly women, but not in participants without that variant. The findings suggest researchers may be able to target brain changes years before memory problems begin.
Related: A Simple Salt Swap Could Prevent 100,000 U.S. Deaths a Year, Scientists Say
Next: How Your Brain Activity Could Signal Alzheimer’s Risk Before You Feel Any Symptoms
Why This Anti-Aging Drug Caught Scientists’ Attention
Rapamycin has attracted attention for its potential effects on biological aging.…